INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER

FERNÁNDEZ|, A.(1)[aandrea.fernandez98@gmail.com];BLANCAS|, I.(2)[iblancas@ugr.es];PÉREZ-RAMÍREZ|, C.(1)[cperezramirez87@gmail.com]; CURA-CUEVAS|, Y.(1)[yacura@uc.cl];CANTUDO CUENCA|, M.R.(1)*[mariar.cantudo.sspa@juntadeandalucia.es]

4CPS-060

(1) Hospital Universitario Virgen de las Nieves, Pharmacy Department, Granada, Spain
 (2) Hospital Universitario Clínico San Cecilio, Oncology Department, Granada, Spain


Background

The response and the toxicity profile associated with **capecitabine** treatment shows great **interindividual variability**. The study of **genetic polymorphisms** of genes involved in the metabolism of capecitabine could help to predict the **response** and **toxicity** to breast cancer treatment.

Aim and objectives

The aim of the study was to evaluate both the **response** and **toxicity** of patients with breast cancer treated with capecitabine, as well as its relation to some **genetic polymorphisms** of genes involved in the **metabolism of capecitabine** (*UMPS, TYMP* y *UPB1*).

Material and methods



Results

A total of **63 patients** were treated with capecitabine in 2021.

- The evaluation of the response (n=38) resulted in: Complete Response: 13.16% (n=5),
 Partial Response: 10.53% (n=4), Stable disease: 10.53% (n=4) and Progessive Disease:
 65.79% (n=25).
- An **association** was observed between the **nulliparity** (p=0.037) of the patients and the **response** to capecitabine (Table 1), as well as between **estrogen** (p=0.024) and

Table 3. Relation between genetic polymorphisms and response to capecitabine therapy.

~	SNPs	Response								
Gen		Genotype	N	No N (%)	Yes N (%)	X ²	Р*			
	rs1801019	CC	1	1 (100)	0 (0)		0.335			
		CG	10	9 (90)	1 (10)	2.187				
		GG	25	17 (68)	8 (32)					
UMPS		С	11	10 (90.9)	1 (9.1)	2.138	0.144			
		G	35	26 (74.3)	9 (25.7)	0.343	0.558			
	rs11479	AA	0	0 (0)	0 (0)		0.404			
		AG	5	3 (60)	2 (40)	0.697				
ТҮМР		GG	31	24 (77.4)	7 (22.6)					
		А	5	3 (60)	2 (40)	0.697	0.404			
	rs2070474	CC	7	7 (100)	0 (0)		0.193			
		CG	17	11 (64.7)	6 (35.3)	3.294				
UPB1		GG	12	9 (75)	3 (25)					
		С	24	18 (75)	6 (25)	0]			
		G	29	20 (69)	9 (31)	2.897	0.089			

progesterone (p=0.006) receptors with the appearance of **toxicity** after treatment (Table 2).

• No association was found between any of the studied polymorphisms with response (Table 3) or toxicity (Table 4) to capecitabine therapy, although most os the results matched those published by other studies.

Table 1. Association between demographic and clinical variables and responde to capecitabine therapy.

	Response									
Variable	Ν	No N (%)	Yes N (%)	X²	P *	Ref Cat.	OR	CI 95%		
Nulliparity	34									
Yes		2 (40)	3 (60)	4 2 2 2	0.027	No	7.0	0.0/ /7.10		
No		24 (82.8)	5 (17.2)	4.333	0.037	No	7.2	0.96-67.19		

Table 2. Association between demographic and clinical variables and toxicity to capecitabine therapy.

	Toxicity								
Variable	N	Mild (Grade 0-2) N (%)	Severe (Grade 3-4) N (%)	Χ²	P*	Ref Cat.	OR	CI 95%	
Estrogen receptors	60								
Positive (+)		37 (84.1)	7 (15.9)	5 00 4	0.004	Manakira	A 11	1.15-	
Negative (-)		9 (56.2)	7 (43.8)	5.084	0.024	Negative	4.11	15.22	
Progesterone receptors	60								
Positive (+)		32 (88.9)	4 (11.1)	7 517	0.007	Magains	E 71	1.62-	
Negative (-)		14 (58.3)	10 (41.7)	7.516	6 0.006	Negative	5.71	23.84	

*p-value by Pearson's Chi-square test. OR: Probability of occurrence. CI: confidence interval.

Table 4. Relation between genetic polymorphisms and toxicity to capecitabine therapy.

	SNPs	Toxicity								
Gen		Genotype	N	Mild (Grade 0-2) N (%)	Severe (Grade 3-4) N (%)	X ²	P*			
UMPS	rs4678145	CC	1	1 (100)	O (O)	0.000	0.137			
		CG	11	6 (54.5)	5 (45.5)	3.980				
		GG	44	36 (81.8)	8 (18.2)					
		С	12	7 (58.3)	5 (41.7)	2.917	0.088			
		G	55	42 (76.4)	13 (23.6)	0.308	0.579			
түмр	rs11479	AA	0	O (O)	O (O)	0 (01	0.438			
		AG	8	7 (87.5)	1 (12.5)	0.601				
		GG	48	36 (75)	12 (25)					
		А	8	7 (87.5)	1 (12.5)	0.601	0.438			
UPB1	rs2070474	CC	10	8 (80)	2 (20)		0.760			
		CG	35	26 (78.8)	7 (21.2)	0.548				
		GG	13	9 (69.2)	4 (30.8)					
		С	43	34 (79.1)	9 (20.9)	0.542	0.462			
		G	46	35 (76.1)	11 (23.9)	0.071	0.791			

Conclusions

The results suggest that there is no relevant relation between the genetic variants analyzed with the response and toxicity to

capecitabine therapy. However, these partly resemble that reflected by other studies. Further research with a bigger patient cohort is required in order to obtain meaningful results.

References

Cura, Y., Pérez Ramírez, C., Sánchez Martín, A., Martínez Martínez, F., Calleja Hernández, M. Á., Ramírez Tortosa, M. del C., & Jiménez Morales, A. (2021). Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. Mutation Research - Reviews in Mutation Research, 788(January). https://doi.org/10.1016/j.mrrev.2021.108391; Huo, X., Li, J., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2021). The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer, 21(1), 1–11. https://doi.org/10.1186/s12885-021-07791-y; Guenter, J., Abadi, S., Lim, H., Chia, S., Woods, R., Jones, M., Rebic, N., Renouf, D. J., Laskin, J., & Marra, M. (2020). Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/1078155220951845; Pellicer, M., García-González, X., García, M. I., Robles, L., Grávalos, C., García-Alfonso, P., Pachón, V., Longo, F., Martínez, V., Blanco, C., Iglesias, I., Sanjurjo, M., & López-Fernández, L. A. (2017). Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological Research, 120, 133–137. https://doi.org/10.1016/j.phrs.2017.03.021

Contact:

Andrea Fernández Alonso

Hospital Universitario Virgen de las Nieves, Pharmacy Department

E-mail: aandrea.fernandez98@gmail.com



